BR112017008284A2 - bifidobactérias ativadas e métodos para uso das mesmas - Google Patents

bifidobactérias ativadas e métodos para uso das mesmas

Info

Publication number
BR112017008284A2
BR112017008284A2 BR112017008284A BR112017008284A BR112017008284A2 BR 112017008284 A2 BR112017008284 A2 BR 112017008284A2 BR 112017008284 A BR112017008284 A BR 112017008284A BR 112017008284 A BR112017008284 A BR 112017008284A BR 112017008284 A2 BR112017008284 A2 BR 112017008284A2
Authority
BR
Brazil
Prior art keywords
methods
activated bifidobacteria
bifidobacteria
activated
composition
Prior art date
Application number
BR112017008284A
Other languages
English (en)
Other versions
BR112017008284A8 (pt
Inventor
Kyle David
Mills David
FREEMAN-SHARKEY Samara
Original Assignee
Evolve Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55761664&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017008284(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Evolve Biosystems Inc filed Critical Evolve Biosystems Inc
Publication of BR112017008284A2 publication Critical patent/BR112017008284A2/pt
Publication of BR112017008284A8 publication Critical patent/BR112017008284A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/529—Infantis

Abstract

a presente invenção refere-se a uma composição e a um método para tratamento de disbiose em bebês. a composição pode incluir uma mistura de bifidobactérias ativadas e um oligossacarídeo complexo, em que o oligossacarídeo complexo pode ser derivado de uma fonte humana ou não humana.
BR112017008284A 2014-10-24 2015-10-23 Bifidobactérias ativadas e métodos para uso das mesmas BR112017008284A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462068553P 2014-10-24 2014-10-24
US201562133243P 2015-03-13 2015-03-13
PCT/US2015/057226 WO2016065324A1 (en) 2014-10-24 2015-10-23 Activated bifidobacteria and methods of use thereof

Publications (2)

Publication Number Publication Date
BR112017008284A2 true BR112017008284A2 (pt) 2017-12-19
BR112017008284A8 BR112017008284A8 (pt) 2023-04-11

Family

ID=55761664

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017008284A BR112017008284A8 (pt) 2014-10-24 2015-10-23 Bifidobactérias ativadas e métodos para uso das mesmas

Country Status (10)

Country Link
US (2) US10716816B2 (pt)
EP (1) EP3209308B1 (pt)
CN (2) CN114376234A (pt)
AU (2) AU2015335601A1 (pt)
BR (1) BR112017008284A8 (pt)
CA (1) CA2965663C (pt)
DK (1) DK3209308T3 (pt)
MX (1) MX2017005260A (pt)
SG (2) SG11201703298SA (pt)
WO (1) WO2016065324A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
SG11201703298SA (en) 2014-10-24 2017-05-30 Evolve Biosystems Inc Activated bifidobacteria and methods of use thereof
JP6868562B2 (ja) 2014-10-31 2021-05-19 ペンデュラム セラピューティクス， インコーポレイテッド 障害の微生物的処置および診断に関する方法および組成物
CA2971108C (en) 2014-12-23 2019-09-17 4D Pharma Research Limited A bacteroides thetaiotaomicron strain and use thereof in reducing inflammation
AU2015370665B2 (en) 2014-12-23 2020-05-14 4D Pharma Research Limited Pirin polypeptide and immune modulation
MX2017010923A (es) * 2015-03-05 2018-01-16 Nestec Sa Composiciones para usar en el mejoramiento de la consistencia o la frecuencia de las heces en infantes o niños pequeños.
MX2017011669A (es) * 2015-03-13 2017-11-06 Evolve Biosystems Inc Composiciones que metabolizan o secuestran monomeros libres de azucar y usos de las mismas.
ES2753779T3 (es) 2015-06-15 2020-04-14 4D Pharma Res Ltd Blautia stercosis y wexlerae para la utilización en el tratamiento de enfermedades inflamatorias y autoinmunes
SG10201912326QA (en) 2015-06-15 2020-02-27 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PL3360559T3 (pl) 2015-06-15 2020-04-30 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MA45287A (fr) 2015-11-20 2018-08-22 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
MX2018010680A (es) 2016-03-04 2019-06-13 4D Pharma Plc Composiciones que comprenden cepas bacterianas.
EP3426270A4 (en) * 2016-03-11 2020-04-01 Evolve Biosystems, Inc. TRANSIENT COMMUNAL MICROORGANISM TO IMPROVE THE COLONAL HEALTH
CN117385064A (zh) 2016-07-01 2024-01-12 英凡特健康有限公司 促进哺乳动物免疫系统成熟的方法
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
JP7212945B2 (ja) 2017-05-22 2023-01-26 フォーディー ファーマ リサーチ リミテッド 細菌株を含む組成物
TW201907931A (zh) 2017-05-24 2019-03-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
MD3638271T2 (ro) 2017-06-14 2021-03-31 4D Pharma Res Ltd Compoziții cuprizând tulpini bacteriene
ES2917415T3 (es) 2017-06-14 2022-07-08 4D Pharma Res Ltd Composiciones que comprenden una cepa bacteriana
CN107365705B (zh) * 2017-07-14 2021-01-12 江苏微康生物科技有限公司 一种油溶性益生菌冻干菌粉的冻干保护剂及其应用
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
WO2019055718A1 (en) * 2017-09-13 2019-03-21 Evolve Biosystems, Inc. METABOLOMIC REVISION OF MAMMALIAN INFANTS
US20200345055A1 (en) 2018-01-17 2020-11-05 Evolve Biosystems, Inc. Activation of conditionally-expressed oligosaccharide pathways during fermentation of probiotic strains
EP3801557A4 (en) * 2018-05-30 2022-03-09 Evolve Biosystems Inc. COMPOSITIONS AND METHOD OF USE FOR BIFIDOBACTERIUM LONGUM SUBSP. COMPETENT FOR H5
CN113163836A (zh) * 2018-06-01 2021-07-23 进化生物系统股份有限公司 促进宿主防御和刺激、扩增和/或重置t细胞库的组合物和方法
US20210161924A1 (en) * 2018-06-19 2021-06-03 Evolve Biosystems, Inc. Novel oligosaccharides for use in prebiotic applications
CN115298499A (zh) * 2020-03-20 2022-11-04 格礼卡姆股份公司 提供固体hmo产品的方法以及由此得到的固体hmo产品
CN111826324A (zh) * 2020-08-05 2020-10-27 厦门惠盈动物科技有限公司 一种鼠李糖乳杆菌菌粉的制备方法
CN114568516A (zh) * 2020-11-30 2022-06-03 内蒙古伊利实业集团股份有限公司 包含长双歧杆菌婴儿亚种与母乳低聚糖的组合物及其应用
CN114568520A (zh) * 2020-11-30 2022-06-03 内蒙古伊利实业集团股份有限公司 包含长双歧杆菌婴儿亚种的婴幼儿配方粉及其应用
EP4258901A1 (en) 2020-12-11 2023-10-18 DSM IP Assets B.V. Improved prebiotic formulations
IT202100024911A1 (it) * 2021-09-29 2023-03-29 Univ Degli Studi Di Napoli Federico Ii Dipartimento Di Fisica Ettore Pancini Prebiotico a base di "scotta" delattosata per la prevenzione e gestione della disbiosi intestinale

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716615A (en) 1992-02-10 1998-02-10 Renata Maria Anna Cavaliere Vesely Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use
RU2180915C1 (ru) 2001-04-28 2002-03-27 Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского Консорциум бифидобактерий и лактобацилл, используемый для приготовления бактериальных препаратов, заквасок для кисломолочных продуктов, ферментированных и неферментированных пищевых продуктов, биологически активных добавок, предназначенных для коррекции микрофлоры детей в возрасте до 3-х лет
AU2004283626B2 (en) * 2003-10-24 2010-07-15 N.V. Nutricia Synbiotic composition for infants
US20070082087A1 (en) * 2005-10-06 2007-04-12 Schweitzer Biotech Company Ltd. Fermented milk products containing bifidobacterium longum and isomalto oligosaccharide and the process for producing the same
EP1776877A1 (en) 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
WO2007140622A1 (en) 2006-06-09 2007-12-13 Nutravital Inc. Dairy-derived probiotic compositions and uses thereof
WO2008033520A2 (en) * 2006-09-15 2008-03-20 The Regents Of The University Of California Bifidobacterial gene sequences and their use
US8197872B2 (en) 2007-05-17 2012-06-12 The Regents Of The University Of California Human milk oligosaccharides to promote growth of beneficial gut bacteria
WO2008153377A1 (en) * 2007-06-15 2008-12-18 N.V. Nutricia Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide
EP2072052A1 (en) * 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
UA32462U (uk) 2008-02-14 2008-05-12 Харьковский Национальный Медицинский Университет Спосіб оцінки ефективності корекції порушень мікробіоценозу кишечнику у дітей молодшого віку з атопічним дерматитом
CA2658440C (en) * 2008-04-04 2016-08-23 Kraft Foods Global Brands Llc Dairy composition with probiotics and anti-microbial system
EP2303294A1 (en) * 2008-05-27 2011-04-06 Nestec S.A. Probiotics to improve gut microbiota
EP2143341A1 (en) * 2008-07-08 2010-01-13 Nestec S.A. Nutritional Composition Containing Oligosaccharide Mixture
PL2352389T3 (pl) * 2008-11-11 2016-07-29 Alimentary Health Ltd Bifidobacterium longum
CN102300575A (zh) 2008-12-02 2011-12-28 普罗莱克塔生物科学公司 人乳渗透物组合物及其制备和使用方法
US9649380B2 (en) 2009-01-12 2017-05-16 Pfizer Italia S.R.L. Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin
US8198872B2 (en) 2009-03-10 2012-06-12 Honeywell International, Inc. Starter-generator with improved excitation
US7888062B1 (en) * 2010-02-01 2011-02-15 Microbios, Inc. Process and composition for the manufacture of a microbial-based product
BR112012020791A2 (pt) 2010-02-19 2016-05-03 Glycom As produção de 6'-o-sialillactose e intermediários
US9200091B2 (en) 2010-07-12 2015-12-01 The Regents Of The University Of California Bovine milk oligosaccharides
EP2465509A1 (en) 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharide composition for treating acute respiratory tract infections
EP2454948A1 (en) * 2010-11-23 2012-05-23 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
EP2465507A1 (en) * 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharide composition for treating skin diseases
CA2822660C (en) 2010-12-31 2021-09-07 Abbott Laboratories Synbiotic combination of probiotic and human milk oligosaccharides
AU2012215042B2 (en) * 2011-02-10 2016-01-14 Société des Produits Nestlé S.A. Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk
US9579353B2 (en) 2011-06-10 2017-02-28 Prothera, Inc. Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
EP2814835B1 (en) * 2012-02-14 2019-04-10 The Regents Of The University Of California Enzymes and methods for cleaving n-glycans from glycoproteins
US10165788B2 (en) 2013-06-17 2019-01-01 The Regents Of The University Of California Methods and compositions for improved digestion of milk oligosaccharides
SG11201703298SA (en) 2014-10-24 2017-05-30 Evolve Biosystems Inc Activated bifidobacteria and methods of use thereof
ES2862176T3 (es) 2014-12-12 2021-10-07 Univ California Reducción de los glucanos de la leche y sus productos de degradación en el intestino del recién nacido

Also Published As

Publication number Publication date
EP3209308A1 (en) 2017-08-30
US20170304375A1 (en) 2017-10-26
US10716816B2 (en) 2020-07-21
SG11201703298SA (en) 2017-05-30
EP3209308A4 (en) 2018-06-27
EP3209308B1 (en) 2022-08-03
DK3209308T3 (da) 2022-10-03
CN114376234A (zh) 2022-04-22
CA2965663A1 (en) 2016-04-28
SG10202002593SA (en) 2020-05-28
WO2016065324A1 (en) 2016-04-28
CN107249611A (zh) 2017-10-13
BR112017008284A8 (pt) 2023-04-11
AU2015335601A1 (en) 2017-06-01
MX2017005260A (es) 2018-01-30
US20200397837A1 (en) 2020-12-24
AU2021204822A1 (en) 2021-08-05
CA2965663C (en) 2023-04-04

Similar Documents

Publication Publication Date Title
BR112017008284A2 (pt) bifidobactérias ativadas e métodos para uso das mesmas
HK1252821A1 (zh) 用於治療具有rtk突變細胞的患者的組合物和方法
MX2021014709A (es) Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes.
IL249061B (en) Combination, formulation and method of administration of the combination or formulation to animals
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR112017009004A2 (pt) composições e métodos compreendendo bactérias para melhorar o comportamento em distúrbios do desenvolvimento neurológico
BR112017006664A2 (pt) terapias de combinação
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
PE20180260A1 (es) Metodos y kits para tratar la depresion
BR112016029226A2 (pt) métodos e composições para o tratamento de úlceras
BR112015015870A2 (pt) composição farmacêutica
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
BR112018001260A2 (pt) mistura aquosa, composição seca por congelamento, e, métodos para imunizar um indivíduo humano e para preparar uma composição.
BR112017014280A2 (pt) métodos de transdiferenciação e métodos de uso da mesma
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
BR112016018085A2 (pt) composições sinérgicas de suplemento dietético para prevenção, tratamento ou controle de doenças inflamatórias e respectivo método de aplicação das composições sinérgicas
BR112016019825A2 (pt) anticorpos do fator bb do complemento
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
MX2017000775A (es) Vacunas de meningococos.
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
BR112017014107A2 (pt) composição nutricional útil no tratamento de pacientes com ibd
BR112016023754A2 (pt) ?uso de lactobacillus paracasei para promover recuperação da diversidade da microbiota intestinal após disbiose?

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: INFINANT HEALTH, INC. (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]